Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported financial results for the fourth quarter and full year ended December 31, 2025, citing growth in sales of its dermatology …
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will host a conference call and live webcast Wednesday to discuss its financial results for the fourth quarter …
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has appointed Chris Chapman as chief commercial officer to lead its U.S. commercial organization and support global expansion efforts.
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said its partner, Torii Pharmaceutical Co. Ltd., has launched YCANTH in Japan for the treatment of molluscum contagiosum following regulatory approval.
West Chester-Based Verrica Partner Launches YCANTH in Japan Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it has dosed the first patient in its global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of …
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion Read More WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) raised approximately $50 million through a private investment in public equity, a move the company said will retire its debt facility, strengthen …
Verrica’s $50 Million PIPE Deal Sparks Big Questions About Its Next Growth Phase Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported third-quarter results that highlight accelerating commercial traction for its lead product, YCANTH®, alongside major regulatory and clinical milestones that broaden …
Verrica Posts Strong Q3 as YCANTH Momentum Builds and Late-Stage Pipeline Advances Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has provided positive feedback supporting …
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will present new data on its investigational oncolytic peptide therapy, VP-315, for the treatment of basal cell carcinoma …
Verrica Pharmaceuticals to Present Phase 2 Data on VP-315 at Major Immunotherapy Conference Read More